###begin article-title 0
Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
In proliferative diabetic retinopathy (PDR) and other angiogenesis-associated diseases, increased levels of cytokines, inflammatory cells, growth factors, and angiogenic factors are present. Vascular endothelial growth factor (VEGF) appears to play a central role in mediating microvascular pathology in PDR. The purpose of the present study was to search for the association between the -634 C/G polymorphism of the VEGF gene and PDR. Moreover, it was hoped to determine whether serum and vitreous levels of VEGF are affected by genetic factors.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
This cross-sectional case-control study enrolled 349 unrelated Slovene subjects (Caucasians) with type 2 diabetes mellitus. The case group consisted of 206 patients with an advanced form of PDR and for whom vitrectomy was performed, and the control group had 143 patients who had no clinical signs of diabetic retinopathy but did have type 2 diabetes of more than 10 years duration. To analyze the genotype distribution we had to compare the genotype frequencies in diabetics with PDR (cases, n=206) and diabetics without diabetic retinopathy (control group, n=143). Additionally, to evaluate the effect of diabetes on the VEGF serum levels 2 groups, diabetics and non diabetics, were compared. First group were diabetics (diabetics with PDR, n=104), and second group were 29 subjects without diabetes.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
The -634 C/G VEGF polymorphism was not associated with PDR. Mean serum and vitreous levels of VEGF were statistically significantly higher in PDR in comparison to the control group. Moreover, significantly higher serum and vitreous levels of VEGF were demonstrated in diabetics with the CC genotype compared to those with the other (CG + GG) genotypes.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
VEGF is an important cytokine in PDR. Despite the effect of the -634 C/G VEGF polymorphism on serum and vitreous levels of VEGF in PDR, it failed to contribute to the genetic susceptibility to PDR.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 629 630 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 820 821 820 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 958 962 958 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1218 1219 1218 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1223 1225 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
In proliferative diabetic retinopathy (PDR) and other angiogenesis-associated diseases, increased levels of cytokines, inflammatory cells, growth factors, and angiogenic factors are present [1-5]. Vascular endothelial growth factor (VEGF) appears to play a central role in mediating microvascular pathology in PDR. VEGF is capable of inducing the earliest changes in diabetic retinopathy such as leukostasis and blood-retinal barrier breakdown [6,7] as well as macular edema and neovascularization in progression of diabetic retinopathy [1]. In the vitreous of patients with PDR, VEGF levels have been found to be increased [1,2,4,5]. Although diabetes duration and inadequate glycemic control are important risk factors in the development of PDR, genetic factors may play a significant role in the pathogenesis of PDR [8,9]. There is considerable variation in VEGF expression among individuals, with several different polymorphisms being reported [10]. The VEGF 634 C/G () polymorphism in the 5'-untranslated region has been reported to be associated with variations in VEGF serum concentrations and with a susceptibility to disorders, such as diabetic retinopathy, diabetic nephropathy, and cardiovascular diseases [8,10-13].
###end p 11
###begin p 12
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
To investigate the impact of genetic polymorphisms of VEGF on PDR in a Slovenian population (Caucasians) with type 2 diabetes, we searched for the association between the -634 C/G VEGF polymorphism and PDR in subjects with type 2 diabetes. Moreover, the aim of the study was to determine the serum and vitreous levels of VEGF of patients with PDR, and whether serum and vitreous levels of VEGF are affected by genetic factors.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 14
###begin p 15
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 951 953 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 84 87 <span type="species:ncbi:9606">men</span>
###xml 93 98 <span type="species:ncbi:9606">women</span>
###xml 211 219 <span type="species:ncbi:9606">Patients</span>
###xml 381 389 <span type="species:ncbi:9606">Patients</span>
This cross-sectional case-control study enrolled 349 (age range 35 to 87 years; 152 men, 197 women) unrelated Slovene subjects (Caucasians) with type 2 diabetes mellitus who had a defined ophthalmologic status. Patients were classified as having type 2 diabetes according to the current American Diabetes Association criteria for the diagnosis and classification of diabetes [14]. Patients were recruited from the Eye Clinic of the University Medical Centre Ljubljana between January 2002 and April 2007. Fundus examination was performed by a senior ophthalmologist (M.G.P.) after pupil dilatation (tropicamide and phenylephrine 2.5%) using slit-lamp biomicroscopy with non-contact lens, and was electronically documented with a 50degrees-angle fundus camera (Topcon-TRC 40-IX; Topcon, Tokyo, Japan). Staging of diabetic retinopathy was determined according to the Early Treatment Diabetic Retinopathy Study Research Group retinopathy severity scale [15].
###end p 15
###begin p 16
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
The study group consisted of 206 patients with an advanced form of PDR (new vessel formation as well as fibrous proliferation with or without vitreous hemorrhage) in whom vitrectomy was indicated and performed due to vitreous hemorrhage, macular detachment, or macular threatening detachment. The control group consisted of 143 patients who had type 2 diabetes of more than 10 years duration but had no clinical signs of diabetic retinopathy.
###end p 16
###begin p 17
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
In 68 out of 206 patients with PDR (71 eyes) 0.3 ml vitreous fluid samples were obtained by vitreoretinal surgery. The study excluded patients who had previous vitrectomy, neovascularization of no diabetic etiology, recent vitreous hemorrhage (less than two months), or a history of ocular inflammation and photocoagulation in the preceding three months.
###end p 17
###begin p 18
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
Macular edema was defined as being clinically significant based on observations rendered by the Early Treatment Diabetic Retinopathy Study [16]. PDR was found to be active in 54 eyes and inactive in 17 eyes, according to the method reported by Aiello and associates [1]. Neovascularization was considered to be active if new vessels were perfused, multibranching iridic, or preretinal capillaries; it was considered to be inactive if previously documented active proliferation had regressed fully or if only nonperfused gliotic vessels or fibrosis were present [1]. The extent of retinal laser photocoagulation was classified into three grades: grade 1) no photocoagulation; grade 2) focal photocoagulation; and grade 3) panretinal photocoagulation (defined as extensive photocoagulation in all four quadrants of the retina).
###end p 18
###begin title 19
Sample collection
###end title 19
###begin p 20
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
Fasting serum VEGF levels were analyzed in 104 out 206 of patients with PDR and in 29 patients without diabetes. Vitreous fluid samples (0.3 ml) were obtained by vitreoretinal surgery (from the midvitreous at the initial stage of vitrectomy by aspiration into a 2 ml syringe attached to the vitreous counter before starting intravitreal infusion of balanced salt solution) from 71 eyes of 68 consecutive patients with PDR, and from 17 eyes of 17 consecutive nondiabetic patients in whom vitrectomy was performed because of idiopatic macular hole [17]. Vitreous was cut and aspirated into a 2 ml syringe attached to the vitreous cutter before starting intravitreal infusion of balanced salt solution.
###end p 20
###begin title 21
Single nucleotide polymorphism -634 C/G gene polymorphisms and diabetic retinopathy
###end title 21
###begin p 22
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 615 616 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The -634 C/G VEGF polymorphism was evaluated as described previously [8]. Genotype determination: Genomic DNA was isolated from peripheral blood lymphocytes by standard methods and stored at -20 degreesC. Genotyping was carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. In brief, each PCR reaction (20 mul) contained 0.4 mul 10 mM dNTP (Gibco), 2 mul 10-X PCR buffer (Gibco), 1.2 mul 25 mM MgCl2 (final concentration 1,5 mM), 1 mul 10 muM of each primer (5'-TTG CTT GCC ATT CCC CAC TTG A-3', 5'-CCG AAG CGA GAA CAG CCC AGA A-3'), 0.7 mul (500 ng) DNA, 12.5 mul H20, 1 mul 5% DMSO, 0,5 unit of AmliTaq Gold DNA-polymerase (Applied Biosystems). Cycling parameters were as follows: 3 min 94 degreesC for primary denaturation, followed by 30 cycles of 1 minute 94 degreesC and 1 minute 59 degreesC, 1 minute 72 degreesC. After digestion for 16 hours at 65 degreesC by 1 unit of the restriction enzyme BsmFI, the restriction products were electrophoresed on a 2.0% agarose gel and then visualized using ethidium bromide staining. The -634G allele result in the gain of a BsmFI site. Two investigators (B.P., D.P.), blinded for case or control status of the DNA sample, performed the genotype classification.
###end p 22
###begin title 23
VEGF serum concentration assay
###end title 23
###begin p 24
For the determination of fasting serum VEGF concentration (isoform VEGF 165), we used a solid phase sandwich ELISA, which involved two kinds of highly specific antibodies (hVEGF Assay Kit; IBL Co., Ltd., Takasaki-shi, Gunma, Japan). In our study the respective coefficient of variation (CV; %) were between 3 and 5.5 for interassay measurements, and between 2.6 and 5.3 for intraassay measurements.
###end p 24
###begin p 25
The vitreous VEGF concentration was determined with the cytometric bead array method (CBA; BD Biosciences, San Diego, CA). The samples were collected in sterile tubes, rapidly frozen and then stored at -80 C until analyzed. VEGF concentrations were measured using CBA (BD Biosciences). The VEGF capture beads were mixed with phycoerythrin - conjugated detection antibodies. These capture beads were incubated with recombinant standards or test samples (vitreous) to form sandwich complexes. Two-color flow cytometric analysis was performed using a FACSCalibur flow cytometer (BD Biosciences). Data were acquired and analyzed using Becton Dickinson Cytometric Bead Array CBA software, and concentrations were determined from the standard curves, plotting recombinant calibrator concentration versus FL-2 mean fluorescence intensity.The use of this method made it possible to detect two of the four VEGF isoforms (VEGF 121 and VEGF 165).
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 141 142 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 315 316 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 340 341 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
We used a nonparametric Mann-Whitney test and Kruskal-Wallis test for multiple group comparison or the Student t-test as appropriate. The chi2 test was used to compare discrete variables and to compare genotype distributions. In addition, all variables that showed significant differences by univariate methods (chi2 test, unpaired Student t test) were analyzed together in a logistic regression analysis. Statistical analysis was performed using the SPSS program for Windows version 14 (SPSS Inc. Chicago, IL).
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 68 75 68 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
The characteristics of the cases and control subjects are listed in Table 1. Cases had earlier onset of diabetes (45.2+/-12.1 years vs. 53.3+/-12.1 years; p<0.001) and longer duration (19.2+/-8.7 years vs. 16.5+/-6.6; p=0.009) of type 2 diabetes compared to controls diabetics without diabetic retinopathy). Additionally, they had higher incidence of insulin therapy than the controls (diabetics without diabetic retinopathy). There were no significant differences in hypertension, smoking, total, high density lipoprotein (HDL) cholesterol, and low density lipoprotein (LDL) cholesterol, and triglyceride levels between the cases and controls.
###end p 29
###begin title 30
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Characteristics of patients with proliferative diabetic retinopathy (PDR; cases) and patients without diabetic retinopathy (controls).
###end title 30
###begin p 31
Cases had earlier onset of diabetes and longer duration of type 2 diabetes compared to controls (diabetics without diabetic retinopathy). Additionally, they had higher incidence of insulin therapy than the controls (diabetics without diabetic retinopathy). Numbers are given as n (%). Abbreviations: HDL, high density lipoprotein, LDL, low density lipoprotein.
###end p 31
###begin title 32
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Single nucleotide polymorphism -634 C/G VEGF polymorphisms and PDF
###end title 32
###begin p 33
###xml 55 62 55 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 133 134 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 171 172 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 201 205 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 302 309 298 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
The VEGF genotype distributions in cases and controls (Table 2) were compatible with Hardy-Weinberg expectations (-634 C/G: cases chi2=1.21, p=0.27; -634 C/G: controls chi2=0.29, p=0.59). The -634 C/G VEGF polymorphism was not associated with PDR in a group of Caucasian subjects with type 2 diabetes (Table 2).
###end p 33
###begin title 34
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Distribution of vascular endothelial growth factor genotypes/alleles in patients with proliferative diabetic retinopathy (cases) and in those without diabetic retinopathy (controls).
###end title 34
###begin p 35
###xml 207 214 207 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 408 409 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Distribution of the -634 C/G vascular endothelial growth factor genotypes/alleles was compared between cases and controls. The frequencies of genotypes and alleles are shown in percentage and as seen in the Table 3 there are no significant differences between cases and controls in either the frequency of the CC genotype (CC versus CG plus GG: odds ratio 1.1, 95% confidence interval 0.5-2.1; p value 0.7). 1p-value and odds ratio (CC versus CG plus GG), 2p value for allele frequency.
###end p 35
###begin p 36
###xml 56 57 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 84 85 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 160 164 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 350 354 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 392 396 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 454 461 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
The variables that showed significant differences by chi2 test and unpaired Student t test (insulin therapy, diabetes duration, age of diabetes onset) plus the VEGF polymorphism were analyzed together in a logistic regression analysis. In the logistic regression model (diabetes duration, age of diabetes onset, incidence of insulin therapy, and the VEGF polymorphism) the CC genotype of the VEGF polymorphism was not an independent risk factor for PDR (Table 3).
###end p 36
###begin title 37
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Logistic regression analysis for the association with proliferative diabetic retinopathy among type 2 diabetic patients.
###end title 37
###begin p 38
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
The asterisk indicates CI is confidence interval; the double asterisk shows the VEGF -634 C/G polymorphism. In the logistic regression model diabetes duration, age of diabetes onset, and incidence of insulin therapy were demonstrated to be an independent risk factor for PDR, whereas the CC genotype of the VEGF polymorphism was not an independent risk factor for PDR. The odd ratio for the CC genotype of the -634 C/G VEGF gene polymorphism is 1.1, 95% confidence interval is 0.7-1.6; p=0.7.
###end p 38
###begin title 39
VEGF serum levels
###end title 39
###begin p 40
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Fasting serum VEGF levels in 104 PDR patients (55.3+/-25.1 ng/l) were significantly higher from those of 29 controls without diabetes (13.8+/-10.2 ng/l; p<0.001). To analyze the genotype distribution we had to compare the genotype frequencies in diabetics with PDR (cases, n=206) and diabetics without diabetic retinopathy (control group, n=143). However, to evaluate the effect of diabetes on the VEGF serum levels 2 groups, diabetics and non-diabetics, were compared. First group were diabetics (diabetics with PDR, n=104), and second group were 29 subjects without diabetes.
###end p 40
###begin p 41
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Moreover, we found significantly higher VEGF serum levels in 24 PDR patients with the CC genotype (60.4+/-32.1 ng/l) compared to 80 PDR patients with the other (CG + GG) genotypes (44.1+/-23.5 ng/l; p<0.01); 24 PDR patients with the CC genotype did not differ in clinical parameters (age, diabetes duration, age of diabetes onset, lipids, blood pressure, incidence of insulin therapy, sex distribution, incidence of smoking) from 80 PDR patients with the other genotypes (data not shown).
###end p 41
###begin p 42
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
We failed, however, to demonstrate statistically significant differences in fasting serum VEGF levels between patients with macular edema (62.1+/-39.1 ng/l ) and patients without macular edema (54.4+/-34.7 ng/l; p=0.4). Moreover, we failed to demonstrate statistically significant differences in fasting serum VEGF levels between patients with active neovascularization (56.3+/-41.8 ng/l ) and patients without active neovascularization (62.8+/-26.6 ng/l; p=0.5)
###end p 42
###begin title 43
VEGF vitreous levels
###end title 43
###begin p 44
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
Vitreous VEGF levels were analyzed in 71 eyes of 68 patients with PDR, and from 17 eyes of 17 patients without diabetes in whom vitrectomy was performed due to idiopatic macular hole [17]. Mean vitreous levels of VEGF were statistically significantly higher in diabetic patients with PDR (5283.51+/-5274.12 pg/ml )in comparison to the control group (17.40+/-12.57 pg/ml; p<0.001).
###end p 44
###begin p 45
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
Vitreous VEGF levels were significantly higher in 12 eyes from 12 patients with the CC genotype (6061.52+/-5341.69 pg/ml ) compared to 59 eyes from 56 subjects with the other (CG + GG) genotypes (3026.43+/-2842.17 pg/ml; p<0.01); 12 PDR eyes from 12 PDR patients with the CC genotype did not differ in clinical parameters (age, diabetes duration, age of diabetes onset, lipids, blood pressure, incidence of insulin therapy, sex distribution, incidence of smoking, and incidence of panretinal photocoagulation) from 59 PDR eyes from 56 patients with the other genotypes (data not shown).
###end p 45
###begin p 46
Macular edema was present in 37 out of 71 eyes with PDR. Significantly higher vitreous VEGF levels were demonstrated in the eyes with macular edema (6567.96+/-5780.66 pg/ml) compared to 34 eyes without macular edema (3885.73+/-4322.94 pg/ml; p=0.02).
###end p 46
###begin p 47
Additionally, we wanted to compare vitreous VEGF levels between active stage of PDR (54 eyes out of 71 in whom vitrectomy was performed) and inactive stage of PDR (17 eyes out of 71 in whom vitrectomy was performed). Statistically significant differences between active (n=54) and inactive stages (n=17) of PDR were demonstrated in vitreous levels of VEGF (6666.25+/-5341.69 pg/ml versus 891.28+/-478.24 pg/ml; p<0.001).
###end p 47
###begin p 48
The extent of laser photocoagulation was related to the vitreous level of VEGF. In the group of 13 eyes with no laser photocoagulation (7541.46+/-6323.89 pg/ml), the VEGF level was significantly higher compared to the group of 32 eyes with incomplete photocoagulation (6631.64+/-5543.10 pg/ml) or the group of 26 eyes with photocoagulation in all four quadrants (2495.3+/-2743.56 pg/ml; p=0.001).
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 993 1004 993 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF C-634G</italic>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
In our study we analyzed the VEGF -634 C/G polymorphism as a potential genetic marker of PDR. The VEGF -634 C/G polymorphism was not associated with PDR in a group of Caucasians with type 2 diabetes. In accordance with our study, Awata and coworkers [8] failed to demonstrate an association between the CC genotype of the VEGF -634 C/G polymorphism and PDR, but they reported an association with diabetic retinopathy. They compared 70 Japanese patients with PDR (22.9% ) to 118 Japanese diabetics without diabetic retinopathy (10.3%), and they failed to demonstrate a statistically significant difference (p=0.081) in the frequency of the CC genotype [8]. Suganthalakshmi and coworkers [12] compared 120 Indian patients with diabetic retinopathy (17.5%) to 90 diabetics without diabetic retinopathy (30%), and they failed to demonstrate a statistically significant difference in the frequency of the CC genotype (p=n.s.). Moreover, Awata and coworkers [13] have recently demonstrated that the VEGF C-634G polymorphism is a genetic risk factor for diabetic macular edema as well as diabetic retinopathy.
###end p 50
###begin p 51
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 919 923 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
Serum VEGF levels were found to be affected by genetic factors (the VEGF -634 C/G polymorphism). We analyzed fasting serum VEGF levels in 104 PDR patients and found significantly higher VEGF serum levels in 24 patietns with the CC genotype compared to 80 patients with the other (CG + GG) genotypes. The VEGF -634 C/G polymorphism is most probably a functional polymorphism, since significantly higher VEGF serum levels have also been reported in healthy subjects with the CC genotype of the C(-634)G polymorphism compared to those with the other genotypes [8]. It was reported that a -634G>C substitution enhanced VEGF expression at both transcriptional and translational levels [18]. Additionally, fasting serum VEGF levels in 104 diabetics with PDR were significantly higher from those of 29 controls without diabetes. Several environmental and genetical factors (hypoxia, hyperglycemia, oxydative stress, ischemia, VEGF gene polymorphism) influence serum VEGF levels [8,19].
###end p 51
###begin p 52
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
In our study, vitreous VEGF levels were found to be affected by genetic factors (VEGF -634 C/G polymorphism) and by local factors in the eyes (extent of laser photocoagulation). Vitreous VEGF levels were affected by the VEGF -634 C/G polymorphism. Vitreous VEGF levels were significantly higher in 12 PDR patients with the CC genotype compared to 56 PDR patients with the other (CG + GG) genotypes. In our study as well as in other studies it was demonstrated that in PDR the extent of laser photocoagulation significantly affects VEGF level [1,4].
###end p 52
###begin p 53
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
Vitreous VEGF levels were statistically higher in PDR eyes in comparison to the control group without diabetes, which is in agreement with other studies [1,3-5]. In our study, however, the levels of VEGF were higher than in other studies. The reason for this discrepancy is probably due to different methods of VEGF detection [20]. Moreover, vitreous VEGF levels were significantly higher in 12 PDR patients with the CC genotype compared to 56 PDR patients with the other (CG + GG) genotypes. We speculate that vitreous VEGF levels were also found to be affected by genetic factors.
###end p 53
###begin p 54
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
Significantly higher vitreous VEGF levels were demonstrated in the eyes with macular edema compared to the eyes without macular edema. Our findings are in accordance with the findings of Funatsu and coworkers [4]. They demonstrated elevated vitreous VEGF in nonproliferative diabetic macular edema [1,3-5]. Moreover, vitreous levels of VEGF were elevated in active neovascularization in PDR that is in agreement with other reports [1,21].
###end p 54
###begin p 55
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
VEGF is an important mediator in pathogenesis of diabetic retinopathy [8,13,18,22]. In the present study we demonstrated that the VEGF -634 C/G polymorphism affects the vitreous and serum levels of VEGF in patients with PDR, whereas the association, on the other hand, has not been demonstrated between the VEGF -634 C/G polymorphism and PDR. We speculate that other factors are more important than the VEGF -634 C/G polymorphism in the pathogenesis of advanced form of PDR (our group of patients with PDR in whom vitrectomy was performed).
###end p 55
###begin p 56
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
In conclusion, VEGF is an important cytokine in PDR. The serum and vitreous VEGF levels were statistically higher in PDR eyes in comparison to the control group. Despite the effect of the VEGF -634 C/G polymorphism on serum and vitreous levels of VEGF in PDR, we found the VEGF -634 C/G polymorphism failed to contribute to the genetic susceptibility to PDR.
###end p 56
###begin title 57
Acknowledgments
###end title 57
###begin p 58
The authors thank Mojca Pirc, B.A., for revising the English.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Comment in: Engl J Med. 1994 Dec 1;331(22):1519-20.
###end article-title 60
###begin article-title 61
Hypoxic regulation of vascular endothelial growth factor in retinal cells.
###end article-title 61
###begin article-title 62
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
###end article-title 62
###begin article-title 63
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
###end article-title 63
###begin article-title 64
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
###end article-title 64
###begin article-title 65
VEGF-initiated blood-retinal barrier breakdown in early diabetes.
###end article-title 65
###begin article-title 66
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
###end article-title 66
###begin article-title 67
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.
###end article-title 67
###begin article-title 68
A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes.
###end article-title 68
###begin article-title 69
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production.
###end article-title 69
###begin article-title 70
###xml 62 67 <span type="species:ncbi:9606">human</span>
Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.
###end article-title 70
###begin article-title 71
Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy.
###end article-title 71
###begin article-title 72
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes.
###end article-title 72
###begin article-title 73
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
###end article-title 73
###begin article-title 74
Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification ETDRS report number 10
###end article-title 74
###begin article-title 75
Photocoagulation for diabetic macular edema: ETDRS Report 1.
###end article-title 75
###begin article-title 76
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy.
###end article-title 76
###begin article-title 77
New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation
###end article-title 77
###begin article-title 78
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
###end article-title 78
###begin article-title 79
Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous.
###end article-title 79
###begin article-title 80
Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization.
###end article-title 80
###begin article-title 81
Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.
###end article-title 81

